Galien Foundation: Synopsis


The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.

The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.


The Galien Foundation is a non-profit foundation 501(c)(3). Funding support comes from its subscribing members and from external donations.



The Galien Foundation Board comprises a team of highly-experienced experts from the life science industry. Board members possess complementary yet diverse expertise gained in R&D, commercial operations, marketing & communications, finance, legal and regulatory leadership positions.

Awards Committee

The awards committee is composed of highly distinguished individuals from the scientific and research communities. In addition to outstanding academic credentials, committee members have demonstrated expertise and understanding of human therapeutics, and are familiar with healthcare issues.

Members & Partners

Members & partners share a common interest in fostering healthcare issues and represent a range of professional, industrial and individual interests. Members include representatives from the following industry sectors:


Healthcare Providers & Payors

Consulting Firms

Patient Advocates


Public and Investor

Relations firms

Medical  Communications

Insurance companies


Legal Profession



Medical Devices

Finance & Banking


Accounting Profession


The Foundation works through complementary tracks:
1.     advocacy to build policies and best practices supportive of the private-sector research enterprise;
2.     educating key stakeholders, including the media, about the contributions of the scientific method in driving patient-centric approaches to drug discovery and development; and
3.     promoting productive partnerships between our Corporate Members and the patient, provider and payer communities, ranging from governments and professional associations to international organizations, academia, the media, and NGOs.
4.     recognition of outstanding achievements and development of new treatments for human conditions.


Since its inception in 2009, the two primary activities of the Galien Foundation have been the Prix Galien Awards Ceremony, and the Galien Forum, which began in 2010. Beginning in early 2012 the Foundation, in its role as a world forum for life sciences, will begin a program of expanded activities.

These new undertakings will address shared issues and opportunities across industry. Working with our Corporate Members, our goal is to define strategies and solutions through activities such as innovation roundtables, private dialogues with key policy makers, and access to research from think-tanks and other influencers. Participants and partners from academia, government, regulatory agencies, NGOs, the commercial services sector and patients’ advocacy groups may also be included as appropriate.

Summary of Activities


The Galien Forum

This annual meeting has become a best-in-class event for senior thought-leaders in the life sciences field. The roundtable-based Forum is rapidly becoming a 'must-attend' for pharmaceutical and biotech industry executives, policymakers, academic researchers and investors.

Prix Galien Awards Ceremony

The Prix Galien awards three prizes for therapeutics: the Best Pharmaceutical Agent (i.e. small molecule), the Best Biotechnology Product, and the Best Medical Device or Diagnostic approved in the USA in the past five years.


The Pro Bono Humanum award recognizes outstanding work or efforts that have helped to improve the human condition through the application of pharmaceutical science to problems of developing or underserved populations worldwide.

Pioneering Spirit of Innovation Award
(to be introduced in 2012)

The Pioneering Spirit of Innovation Award is the first award for scientific innovation that does not lead to an approved new drug or medical treatment option; but, is nevertheless ground breaking, scientifically important or provides important consequences advancing medical knowledge and practice.

Galien Scholars (to be introduced in 2012)

A grant program recognizing young investigators of outstanding promise in science relevant to the advancement of human health. The program provides grants of money to Departments of Pharmacology of U.S. medical research institutions with 501(c)(3) status to support the independent research of the Galien Scholars.


Innovation Roundtables

Multidisciplinary experts examine and develop initiatives on issues such as caring for neglected diseases, supporting emerging markets, the role of biopharma in public health programs etc.

Working Groups

Composed of corporate members whose goal is to study and report on topics of special interest related to the US marketplace.

Patient Advocacy & Collaboration

By engaging with patient advocacy groups members will gain clearer understanding of the patient-centric needs and issues related to new therapeutic development

Galien International

A forum for collaboration and sharing of best practices amongst the national and regional Prix Galien organizations

The Galien Young
Leadership Series

Sharing similarities with The World Economic Forum (WEF) we will invite young researchers to participate in a series of debates and discussions on matters of discovery and development.